



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

March 2019





© 2019 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

**BC Centre for Excellence in HIV/AIDS
Drug Treatment Program**

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

March 2019

N = 7426



Health Authority	Male	Female	All
FRASER	1435	425	1860
INTERIOR	402	100	502
NORTHERN	128	80	208
VANCOUVER COASTAL	3448	445	3893
VANCOUVER ISLAND	772	153	925
	6185	1203	7388
		Unknown/not stated:	38
		Total:	7426

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2014 - March 2019)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2014 - March 2019)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (March 2014 - March 2019)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (March 2014 - March 2019)






1.6 Percent Distribution of Active Participants by CD4 Count (March 2014 - March 2019)






1.7 Percent Distribution of Inactive Participants by CD4 Count (March 2014 - March 2019)






1.8 Active and Inactive Participants (March 2014 - March 2019)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (March 2014 - March 2019)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (March 2014 - March 2019)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(March 2014 - March 2019)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (March 2014 - March 2019)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(March 2014 - March 2019)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (March 2014 - March 2019)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(March 2014 - March 2019)





1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (March 2014 - March 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(March 2014 - March 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes






1.18 Baseline CD4 for Antiretroviral First Starts
(March 2014 - March 2019)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(March 2014 - March 2019)**






1.20 Cumulative Resistance Testing Results by Resistance Category (March 2014 - March 2019)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (March 2014 - March 2019)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2019
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	27	5	0	5	5	900	5	44	3
1988	28	7	0	7	7	450	7	<40	3
1989	26	54	1	55	47	460	55	<40	3
1990	25	55	1	56	47	480	55	<40	3
1991	25	38	3	41	31	580	39	<40	3
1992	24	64	5	69	48	575	61	<40	3
1993	24	137	16	153	137	570	144	<40	3
1994	22	79	13	92	72	553	87	<40	3
1995	22	131	23	154	128	570	147	<40	3
1996	20	355	56	411	347	580	393	<40	3
1997	18	290	33	323	274	625	303	<40	3
1998	17	199	45	244	197	560	229	<40	3
1999	17	169	40	209	177	580	195	<40	3
2000	18	128	33	161	139	580	153	<40	3
2001	17	127	29	156	127	568	147	<40	3
2002	16	124	26	150	122	590	145	<40	3
2003	15	158	29	187	153	620	178	<40	3
2004	14	168	40	208	172	600	196	<40	3
2005	13	194	47	241	195	630	222	<40	3
2006	12	196	38	234	191	600	220	<40	3
2007	12	258	46	304	252	610	283	<40	3
2008	11	299	70	369	310	660	352	<40	3
2009	10	329	70	399	326	660	377	<40	3
2010	9	285	72	357	299	630	341	<40	3
2011	8	338	75	413	343	680	380	<40	3
2012	7	283	64	347	287	720	324	<40	3
2013	6	280	67	347	284	670	323	<40	3
2014	5	295	54	349	275	750	326	<40	3
2015	4	302	50	352	305	648	335	<40	3
2016	3	287	54	341	284	650	313	<40	3
2017	2	248	38	286	244	650	265	<40	3
2018	1	240	55	295	253	600	290	<40	3
2019	0	69	13	82	75	520	80	62	3
Total:		6191	1206	7397					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	7295	755	2386	<40	2108	610
FEB-2018	7257	765	1903	<40	1743	610
MAR-2018	7279	774	2049	<40	1828	614
APR-2018	7265	778	2082	<40	1843	620
MAY-2018	7288	780	2148	<40	1926	600
JUN-2018	7289	795	2008	<40	1792	610
JUL-2018	7293	797	2038	<40	1811	600
AUG-2018	7295	801	2092	<40	1873	620
SEP-2018	7250	805	2014	<40	1783	620
OCT-2018	7343	785	2169	<40	1940	610
NOV-2018	7345	789	2091	<40	1809	630
DEC-2018	7361	798	1747	<40	1523	620
JAN-2019	7399	800	2457	<40	2088	610
FEB-2019	7387	808	1855	<40	1520	620
MAR-2019	7426	803	2086	<40	1628	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	1417	3385	78	872	71	380
FEB-2018	1462	3149	79	1036	65	440
MAR-2018	1448	3242	75	59	70	485
APR-2018	1466	3175	71	808	62	484
MAY-2018	1449	3299	91	<40	82	455
JUN-2018	1460	3271	68	2980	64	440
JUL-2018	1465	3268	69	<40	54	555
AUG-2018	1497	3179	63	56	59	490
SEP-2018	1543	2987	88	220	82	415
OCT-2018	1472	3338	79	<50	68	360
NOV-2018	1482	3314	81	83	73	480
DEC-2018	1478	3345	56	259	45	490
JAN-2019	1469	3402	72	70	64	380
FEB-2019	1492	3353	72	111	62	570
MAR-2019	1460	3504	74	885	57	390

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2018	7253	1417	13	12	192	126	55	13218
FEB-2018	7221	1462	11	27	123	168	-32	13255
MAR-2018	7239	1448	17	21	152	134	18	13282
APR-2018	7231	1466	13	15	153	159	-8	13304
MAY-2018	7257	1449	9	12	170	144	26	13329
JUN-2018	7252	1460	13	16	148	153	-5	13351
JUL-2018	7249	1465	13	14	158	154	-3	13377
AUG-2018	7258	1497	9	27	155	159	9	13416
SEP-2018	7211	1543	16	15	154	193	-47	13442
OCT-2018	7308	1472	8	19	217	127	97	13478
NOV-2018	7319	1482	5	9	172	163	11	13504
DEC-2018	7336	1478	11	19	152	142	17	13529
JAN-2019	7372	1469	14	20	190	160	36	13564
FEB-2019	7365	1492	7	16	162	175	-7	13593
MAR-2019	7397	1460	15	14	185	149	32	13613

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2018	58	6730	451	55	7294	0.80%	92.27%	6.18%	0.75%	100.00%
FEB-2018	62	6685	451	59	7257	0.85%	92.12%	6.21%	0.81%	100.00%
MAR-2018	62	6708	454	56	7280	0.85%	92.14%	6.24%	0.77%	100.00%
APR-2018	59	6699	449	58	7265	0.81%	92.21%	6.18%	0.80%	100.00%
MAY-2018	65	6711	455	58	7289	0.89%	92.07%	6.24%	0.80%	100.00%
JUN-2018	61	6722	448	58	7289	0.84%	92.22%	6.15%	0.80%	100.00%
JUL-2018	53	6726	459	55	7293	0.73%	92.23%	6.29%	0.75%	100.00%
AUG-2018	54	6732	453	56	7295	0.74%	92.28%	6.21%	0.77%	100.00%
SEP-2018	51	6682	458	59	7250	0.70%	92.17%	6.32%	0.81%	100.00%
OCT-2018	53	6760	476	54	7343	0.72%	92.06%	6.48%	0.74%	100.00%
NOV-2018	53	6766	476	50	7345	0.72%	92.12%	6.48%	0.68%	100.00%
DEC-2018	52	6783	477	49	7361	0.71%	92.15%	6.48%	0.67%	100.00%
JAN-2019	54	6806	486	53	7399	0.73%	91.99%	6.57%	0.72%	100.00%
FEB-2019	52	6794	492	49	7387	0.70%	91.97%	6.66%	0.66%	100.00%
MAR-2019	57	6828	491	50	7426	0.77%	91.95%	6.61%	0.67%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	10 36%	3321 47%	9 32%	3077 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3636 51%
FEB-2018	13 35%	3322 47%	12 32%	3080 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3585 51%
MAR-2018	10 37%	3341 47%	10 37%	3105 44%	0 0%	60 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	17 63%	3567 50%
APR-2018	5 23%	3348 47%	5 23%	3116 44%	0 0%	56 1%	0 0%	3 0%	0 0%	4 0%	2 9%	333 5%	15 68%	3539 50%
MAY-2018	9 39%	3356 47%	8 35%	3130 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3515 50%
JUN-2018	6 30%	3372 48%	6 30%	3148 45%	0 0%	54 1%	0 0%	5 0%	0 0%	3 0%	1 5%	380 5%	13 65%	3483 49%
JUL-2018	7 28%	3399 48%	7 28%	3176 45%	0 0%	51 1%	0 0%	5 0%	0 0%	3 0%	4 16%	398 6%	14 56%	3450 49%
AUG-2018	13 33%	3396 48%	14 36%	3184 45%	0 0%	50 1%	0 0%	4 0%	0 0%	3 0%	2 5%	415 6%	23 59%	3417 48%
SEP-2018	4 15%	3379 48%	3 12%	3164 45%	1 4%	47 1%	0 0%	4 0%	0 0%	2 0%	4 15%	446 6%	18 69%	3373 48%
OCT-2018	11 31%	3421 48%	9 26%	3207 45%	1 3%	49 1%	0 0%	3 0%	0 0%	2 0%	0 0%	479 7%	25 71%	3384 47%
NOV-2018	9 35%	3429 48%	8 31%	3215 45%	0 0%	47 1%	0 0%	4 0%	0 0%	2 0%	1 4%	491 7%	17 65%	3354 47%
DEC-2018	8 32%	3447 48%	8 32%	3234 45%	0 0%	45 1%	0 0%	4 0%	0 0%	1 0%	2 8%	504 7%	15 60%	3350 47%
JAN-2019	7 21%	3472 48%	7 21%	3259 45%	0 0%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 76%	3360 47%
FEB-2019	13 45%	3469 48%	12 41%	3268 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	543 8%	13 45%	3313 46%
MAR-2019	6 30%	3484 48%	6 30%	3287 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	558 8%	12 60%	3314 46%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2018	18	64%	3712	52%
FEB-2018	24	65%	3679	52%
MAR-2018	17	63%	3673	52%
APR-2018	17	77%	3661	52%
MAY-2018	14	61%	3661	52%
JUN-2018	14	70%	3661	52%
JUL-2018	18	72%	3653	52%
AUG-2018	25	64%	3650	52%
SEP-2018	22	85%	3633	52%
OCT-2018	24	69%	3685	52%
NOV-2018	17	65%	3670	51%
DEC-2018	17	68%	3671	51%
JAN-2019	27	79%	3699	51%
FEB-2019	16	55%	3682	51%
MAR-2019	14	70%	3709	51%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	8 0%	3 30%	1318 45%	7 70%	1418 48%	0 0%	196 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1258 44%	15 100%	1422 49%	0 0%	190 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1247 43%	10 91%	1439 50%	0 0%	188 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1223 43%	11 100%	1437 50%	0 0%	182 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1210 43%	5 100%	1443 51%	0 0%	181 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1191 42%	11 92%	1433 51%	0 0%	176 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 20%	1171 42%	7 70%	1441 52%	1 10%	169 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1157 42%	11 69%	1425 52%	0 0%	166 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%
SEP-2018	0 0%	7 0%	1 14%	1134 42%	6 86%	1409 52%	0 0%	159 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
OCT-2018	0 0%	7 0%	3 17%	1123 41%	15 83%	1450 53%	0 0%	153 6%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
NOV-2018	0 0%	6 0%	1 14%	1116 41%	6 86%	1459 53%	0 0%	146 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
DEC-2018	0 0%	5 0%	1 11%	1106 41%	7 78%	1457 54%	1 11%	145 5%	0 0%	0 0%	0 0%	2 0%	0 0%	9 0%
JAN-2019	0 0%	6 0%	1 8%	1099 40%	11 92%	1477 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1071 40%	9 82%	1475 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1052 39%	3 60%	1487 55%	0 0%	134 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%
SEP-2018	0	0%	1	0%
OCT-2018	0	0%	1	0%
NOV-2018	0	0%	1	0%
DEC-2018	0	0%	1	0%
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	3 50%	779 37%	1 17%	263 13%	2 33%	757 36%	0 0%	302 14%
FEB-2018	3 75%	771 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	1 33%	758 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	1 50%	745 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	1 50%	721 36%	0 0%	248 12%	0 0%	725 36%	1 50%	314 16%
JUL-2018	3 60%	723 36%	0 0%	243 12%	0 0%	717 36%	2 40%	314 16%
AUG-2018	2 100%	715 36%	0 0%	238 12%	0 0%	716 36%	0 0%	308 16%
SEP-2018	6 100%	706 36%	0 0%	236 12%	0 0%	712 36%	0 0%	311 16%
OCT-2018	3 60%	696 35%	0 0%	234 12%	0 0%	710 36%	2 40%	324 17%
NOV-2018	8 80%	687 35%	0 0%	230 12%	0 0%	700 36%	2 20%	322 17%
DEC-2018	1 100%	684 36%	0 0%	225 12%	0 0%	696 36%	0 0%	320 17%
JAN-2019	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	2 67%	668 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	3 75%	660 35%	0 0%	224 12%	1 25%	681 36%	0 0%	322 17%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	9 47%	2007 60%	8 42%	632 19%	0 0%	46 1%	2 11%	688 21%
FEB-2018	0 0%	0 0%	16 70%	2028 60%	6 26%	642 19%	0 0%	45 1%	1 4%	676 20%
MAR-2018	0 0%	0 0%	14 100%	2062 61%	0 0%	645 19%	0 0%	43 1%	0 0%	674 20%
APR-2018	0 0%	0 0%	8 67%	2107 61%	4 33%	654 19%	0 0%	44 1%	0 0%	681 20%
MAY-2018	0 0%	0 0%	13 65%	2140 61%	4 20%	665 19%	1 5%	42 1%	3 15%	675 19%
JUN-2018	0 0%	0 0%	7 64%	2173 62%	3 27%	675 19%	0 0%	42 1%	1 9%	676 19%
JUL-2018	0 0%	0 0%	7 58%	2208 62%	4 33%	675 19%	0 0%	43 1%	1 8%	675 19%
AUG-2018	0 0%	0 0%	23 79%	2254 62%	5 17%	675 19%	0 0%	42 1%	1 3%	671 19%
SEP-2018	0 0%	9 0%	5 36%	2261 62%	9 64%	690 19%	0 0%	41 1%	0 0%	656 18%
OCT-2018	0 0%	17 0%	13 76%	2319 63%	4 24%	708 19%	0 0%	40 1%	0 0%	659 18%
NOV-2018	0 0%	17 0%	11 100%	2344 63%	0 0%	704 19%	0 0%	38 1%	0 0%	651 17%
DEC-2018	0 0%	17 0%	13 76%	2368 63%	4 24%	720 19%	0 0%	39 1%	0 0%	652 17%
JAN-2019	0 0%	16 0%	15 75%	2431 63%	4 20%	730 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2443 63%	5 23%	728 19%	0 0%	40 1%	1 5%	653 17%
MAR-2019	0 0%	27 1%	8 62%	2493 64%	5 38%	747 19%	0 0%	38 1%	0 0%	646 16%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2018	2010	27.56	1645	22.55	2596	35.59	117	1.60	55	0.75	871	11.94
FEB-2018	1967	27.10	1630	22.46	2616	36.05	116	1.60	59	0.81	869	11.97
MAR-2018	1978	27.17	1616	22.20	2648	36.37	113	1.55	56	0.77	869	11.94
APR-2018	1936	26.65	1596	21.97	2699	37.15	114	1.57	58	0.80	862	11.87
MAY-2018	1930	26.48	1575	21.61	2739	37.58	114	1.56	58	0.80	873	11.98
JUN-2018	1911	26.22	1564	21.46	2789	38.26	113	1.55	58	0.80	854	11.72
JUL-2018	1887	25.87	1567	21.49	2818	38.64	110	1.51	55	0.75	856	11.74
AUG-2018	1866	25.58	1549	21.23	2863	39.25	111	1.52	56	0.77	850	11.65
SEP-2018	1830	25.24	1532	21.13	2878	39.70	109	1.50	59	0.81	842	11.61
OCT-2018	1852	25.22	1528	20.81	2946	40.12	104	1.42	54	0.74	859	11.70
NOV-2018	1844	25.11	1522	20.72	2967	40.39	106	1.44	50	0.68	856	11.65
DEC-2018	1835	24.93	1511	20.53	3007	40.85	104	1.41	49	0.67	855	11.62
JAN-2019	1833	24.77	1481	20.02	3064	41.41	100	1.35	53	0.72	868	11.73
FEB-2019	1805	24.43	1479	20.02	3087	41.79	99	1.34	49	0.66	868	11.75
MAR-2019	1796	24.19	1474	19.85	3138	42.26	99	1.33	50	0.67	869	11.70

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	21	4	1	5	4	6	325
APR-2018	15	0	0	5	3	5	480
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	14	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	13	450
SEP-2018	15	2	3	1	3	5	405
OCT-2018	19	0	1	2	5	10	525
NOV-2018	9	2	2	2	0	2	185
DEC-2018	19	2	0	5	5	7	380
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	14	1	2	1	6	4	440

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2018	11956	3652
FEB-2018	11987	3668
MAR-2018	12015	3697
APR-2018	12047	3728
MAY-2018	12082	3753
JUN-2018	12094	3756
JUL-2018	12120	3780
AUG-2018	12134	3775
SEP-2018	12157	3796
OCT-2018	12178	3798
NOV-2018	12216	3818
DEC-2018	12220	3813
JAN-2019	12262	3840
FEB-2019	12274	3843
MAR-2019	12312	3881

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
March 2019

N = 7426

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2019

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2019

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2019

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2019

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

March 2019

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	*
	35-49	12	14	*
	50+	25	36	*
	Total HSDA:	43	56	31
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	70	93	51	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	365	490	275	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	13
	35-49	*	*	40
	50+	*	*	92
Total HSDA:	190	253	145	
Total HA:		668	892	502

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		668	892	502

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	531	712	402
Female	137	180	100

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	502	55	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	11
	5 years or more	11	8
	<5 years	14	12
	Total HSDA:	43	31
KOOTENAY BOUNDARY	10 years or more	45	33
	5 years or more	13	10
	<5 years	12	8
	Total HSDA:	70	51
OKANAGAN	10 years or more	223	157
	5 years or more	68	57
	<5 years	74	61
	Total HSDA:	365	275
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	107	76
	5 years or more	39	34
	<5 years	44	35
	Total HSDA:	190	145
Total HA:		668	502

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	393	277
	5 years or more	131	109
	<5 years	144	116
Total HA:		668	502

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	40	59	12	25
KOOTENAY BOUNDARY	68	119	21	43
OKANAGAN	211	910	62	284
THOMPSON/CARIBOO/SHUSWAP	128	495	37	138
Total:	447	1583	132	490

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	93

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	5	5	5
	20-34	29	31	22
	35-49	110	121	80
	50+	220	293	178
	Total HSDA:	364	450	285
FRASER NORTH	0-19	10	10	*
	20-34	104	106	*
	35-49	349	382	*
	50+	530	848	*
	Total HSDA:	993	1346	763
FRASER SOUTH	0-19	7	7	5
	20-34	116	118	88
	35-49	342	389	288
	50+	517	764	431
	Total HSDA:	982	1278	812
Total HA:		2339	3074	1860

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	22	22	12
	20-34	249	255	181
	35-49	801	892	632
	50+	1267	1905	1035
Total HA:		2339	3074	1860

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1776	2357	1435
Female	563	717	425

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1860	51	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	202	153
	5 years or more	86	71
	<5 years	76	61
	Total HSDA:	364	285
FRASER NORTH	10 years or more	533	385
	5 years or more	250	200
	<5 years	210	178
	Total HSDA:	993	763
FRASER SOUTH	10 years or more	522	423
	5 years or more	224	183
	<5 years	236	206
	Total HSDA:	982	812
Total HA:		2339	1860

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	1257	961
5 years or more	560	454
<5 years	522	445
Total HA:	2339	1860

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	139	487	35	66
FRASER NORTH	247	1544	51	246
FRASER SOUTH	212	1428	46	460
Total:	598	3459	132	772

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	185
FRASER NORTH	621
FRASER SOUTH	491
Total:	1297

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	20
	35-49	*	*	66
	50+	*	*	198
	Total HSDA:		332	478
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		167	216
VANCOUVER	0-19	34	36	6
	20-34	441	454	327
	35-49	1416	1594	1039
	50+	2763	4699	2105
	Total HSDA:	4654	6783	3477
Total HA:		5153	7477	3893

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	37	39	7
	20-34	492	506	366
	35-49	1539	1729	1139
	50+	3085	5203	2381
Total HA:		5153	7477	3893

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4535	6561	3448
Female	616	914	445

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3893	53	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	183	150
	5 years or more	81	71
	<5 years	68	63
	Total HSDA:	332	284
RICHMOND	10 years or more	92	68
	5 years or more	38	31
	<5 years	37	33
	Total HSDA:	167	132
VANCOUVER	10 years or more	2654	1899
	5 years or more	1196	893
	<5 years	804	685
	Never on ART	0	0
	Total HSDA:	4654	3477
Total HA:	5153	3893	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2929	2117
5 years or more	1315	995
<5 years	909	781
Never on ART	0	0
Total HA:	5153	3893

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	166	486	50	170
RICHMOND	43	284	11	92
VANCOUVER	587	10636	191	5285
Total:	796	11406	252	5547

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	121

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		312	442
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		121	161
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		723	1020
Total HA:		1156	1623	925

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	101	107	*
	35-49	311	360	*
	50+	738	1150	*
Total HA:		1156	1623	925

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	954	1337	772
Female	202	286	153

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	925	54	530	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	169	142
	5 years or more	70	60
	<5 years	73	61
	Total HSDA:	312	263
NORTH VANCOUVER ISLAND	10 years or more	68	57
	5 years or more	30	24
	<5 years	23	17
	Total HSDA:	121	98
SOUTH VANCOUVER ISLAND	10 years or more	412	301
	5 years or more	152	129
	<5 years	159	134
	Total HSDA:	723	564
Total HA:		1156	925

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	649	500
	5 years or more	252	213
	<5 years	255	212
Total HA:		1156	925

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	191	840	76	196
NORTH VANCOUVER ISLAND	134	262	48	76
SOUTH VANCOUVER ISLAND	209	1752	44	552
Total:	534	2854	168	824

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	50
NORTH VANCOUVER ISLAND	36
SOUTH VANCOUVER ISLAND	108
Total:	194

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		39	47
NORTH WEST	0-19	*	*	0
	20-34	*	*	10
	35-49	*	*	14
	50+	*	*	34
	Total HSDA:		71	109
NORTHERN INTERIOR	0-19	5	5	*
	20-34	18	20	*
	35-49	69	85	*
	50+	87	146	*
	Total HSDA:		179	256
Total HA:		289	412	208

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	*
	20-34	32	35	*
	35-49	106	142	*
	50+	144	228	*
Total HA:		289	412	208

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	175	254	128
Female	114	158	80

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	208	51	540	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	17	8
	5 years or more	14	6
	<5 years	8	5
	Total HSDA:	39	19
NORTH WEST	10 years or more	31	22
	5 years or more	25	22
	<5 years	15	14
	Total HSDA:	71	58
NORTHERN INTERIOR	10 years or more	73	50
	5 years or more	60	51
	<5 years	46	30
	Total HSDA:	179	131
Total HA:		289	208

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	121	80
	5 years or more	99	79
	<5 years	69	49
Total HA:		289	208

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	38	61	6	6
NORTH WEST	71	160	14	29
NORTHERN INTERIOR	104	450	15	176
Total:	213	671	35	211

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	22
NORTHERN INTERIOR	13
Total:	41

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	19	35	12
	THOMPSON/CARIBOO/SHUSWAP	27	45	19
	Total HA:	58	99	42
FRASER	FRASER EAST	42	52	32
	FRASER NORTH	51	87	42
	FRASER SOUTH	73	106	53
	Total HA:	166	245	127
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	49	23
	RICHMOND	12	17	9
	VANCOUVER	498	851	397
	Total HA:	536	917	429
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	79	42
	NORTH VANCOUVER ISLAND	15	24	12
	SOUTH VANCOUVER ISLAND	35	77	28
	Total HA:	101	180	82
NORTHERN	NORTH EAST	10	12	6
	NORTH WEST	32	61	27
	NORTHERN INTERIOR	63	100	50
	Total HA:	105	173	83
Total:		966	1614	763

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	602	1029	477
Female	364	585	286

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	763	51	500	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by





blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

